公开(公告)号：US08440662B2

公开(公告)日：2013-05-14

申请号：US13285227

申请日：2011-10-31

申请人： Roger Astbury Smith ,  Scott Kevin Thompson ,  Subramanya Hosahalli ,  Mallesham Bejugam ,  Srinivas Nanduri ,  Sunil Kumar Panigrahi ,  Natarajan Mahalingam

发明人： Roger Astbury Smith ,  Scott Kevin Thompson ,  Subramanya Hosahalli ,  Mallesham Bejugam ,  Srinivas Nanduri ,  Sunil Kumar Panigrahi ,  Natarajan Mahalingam

IPC分类号： A61K31/535 ,  C07D413/04 ,  C07D413/14

CPC分类号： C07D239/72 ,  A61K31/535 ,  C07D239/42 ,  C07D295/155 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D413/14 ,  C07D471/04

摘要： The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

公开(公告)号：US20120129851A1

公开(公告)日：2012-05-24

申请号：US13285227

申请日：2011-10-31

申请人： Roger Astbury Smith ,  Scott Kevin Thompson ,  Subramanya Hosahalli ,  Mallesham Bejugam ,  Srinivas Nanduri ,  Sunil Kumar Panigrahi ,  Natarajan Mahalingam

发明人： Roger Astbury Smith ,  Scott Kevin Thompson ,  Subramanya Hosahalli ,  Mallesham Bejugam ,  Srinivas Nanduri ,  Sunil Kumar Panigrahi ,  Natarajan Mahalingam

IPC分类号： A61K31/5377 ,  C07D413/04 ,  C07D471/04 ,  A61P29/00 ,  A61P35/02 ,  A61P11/00 ,  A61P9/10 ,  A61P1/00 ,  A61P35/00 ,  C07D413/14 ,  A61P19/02

CPC分类号： C07D239/72 ,  A61K31/535 ,  C07D239/42 ,  C07D295/155 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D413/14 ,  C07D471/04

摘要： The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

摘要翻译： 本申请提供新的取代喹唑啉和吡啶并嘧啶化合物及其药学上可接受的盐。 还提供了制备这些化合物的方法。 通过向患者施用治疗有效量的一种或多种化合物，这些化合物可用于共同调节PI3K和/或mTOR活性。 通过这样做，这些化合物在治疗与PI3K / AKT / mTOR途径失调相关的病症中是有效的。 有利地，这些化合物表现为双重PI3K / mTOR抑制剂。 可以使用这些化合物治疗各种病症，并且包括以炎症或异常细胞增殖为特征的疾病。 在一个实施方案中，该疾病是癌症。